STAT

Opinion: BMJ should retract flawed research paper on chronic fatigue syndrome

The BMJ imprimatur should serve as something more than an advisory that readers have to "reach their own conclusions" about the integrity of research published in the organization's journals.
Empty shoes represent individuals who were too ill to join a demonstration in The Hague, Netherlands, organized by #MillionsMissing to draw attention to people suffering from chronic fatigue syndrome.

Few journals have been more admirable than The BMJ (formerly the British Medical Journal) and some of its sister publications under the BMJ brand in highlighting issues of direct significance to health care consumers. So it is baffling — and troubling — when BMJ editors fail to take appropriate action to address unacceptable lapses in high-profile research they have published.

For years, the reading list for my journalism class on public health and medicine at the University of California, Berkeley, included groundbreaking articles in The BMJ on “disease-mongering” — how pharmaceutical companies have manipulated and misrepresented research data to expand existing diagnostic categories and create new ones. I have also appreciated BMJ’s campaign for open access to trial data and its forays into investigative journalism.

Much of this hard-hitting approach can be attributed to Dr. Fiona Godlee, the Cambridge University-educated physician who has led the organization since 2005. Godlee is both editorial director of BMJ, which publishes dozens of titles, and editor-in-chief of The BMJ, one of the world’s leading medical journals. A 2016 profile of Godlee in STAT called her a “crusading editor” who “aims to shake things up in science.” The BMJ, she told STAT, is “a campaigning journal.”

That’s why I am disappointed at how BMJ and Godlee have handled a seriously problematic paper in a field I know well — behavioral

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Moderna Covid-flu Vaccine, A Paused Pfizer Study, And More
Moderna announced its combination Covid and flu vaccine generated stronger immune responses in older adults in a Phase 3 trial than individual vaccines.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Novo’s Wegovy Approval In China, A Merck KGaA Cancer Trial Failure, And More
Novo Nordisk's weight loss drug Wegovy has been approved in China, the country estimated to have the highest number of overweight or obese people.
STAT1 min readIntelligence (AI) & Semantics
STAT+: Q&A: Defining Responsible AI In Health Care, With CHAI CEO Brian Anderson
CHAI CEO Anderson wants to build public trust in AI and empower patients and providers to have more informed conversations.

Related Books & Audiobooks